Borderline ovarian tumors.
Borderline tumor of the ovary (BOT) is an epithelial tumor with a low rate of growth and a low potential to invade or metastasize. This tumor often is associated with a significantly better prognosis than epithelial ovarian cancer. Most tumors are either serous or mucinous in histology and present as early stage lesions. However, stage III lesions with peritoneal implants are not uncommon. Patients with early stage lesions have an excellent prognosis. Patients with higher stage lesions have a worse prognosis. Long-term follow-up of patients with BOT is required since the tumor can recur up to 20 years after the initial diagnosis. Recently, investigators have begun to identify subsets of patients with a worse prognosis, such as patients with aneuploid tumors. Treatment for early stage lesions is surgical and conservative surgery can be accomplished successfully in younger patients who desire to maintain fertility. Treatment for later stage lesions has been approached in a variety of ways. All approaches initially begin with maximal cytoreductive surgery. Studies suggest that early stage disease should be managed with surgery alone. Conflicting results on the usefulness of adjuvant therapy for patients with later stage disease have been obtained. At this time, the usefulness of adjuvant therapy for advanced disease remains undetermined. Further understanding of the basis of the disease and analysis of specific higher risk subsets might identify patients in whom adjuvant therapy could be tested in the setting of controlled clinical trials.
Link
C J
CJ
Human Gene Therapy Research Institute, Central Iowa Health Systems, Des Moines 50325, USA.
Reed
E
E
Sarosy
G
G
Kohn
E C
EC
D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D006801:Humans; D009366:Neoplasm Seeding; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial; D010051:Ovarian Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000556:secondary; D011379:Prognosis; D016019:Survival Analysis
D014408:Biomarkers, Tumor